
Zhiqiang Song
Articles
-
Dec 28, 2024 |
mdpi.com | Zhiqiang Song
Altmetric announcement Help format_quote Cite thumb_up ... Endorse Need Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.
-
Nov 13, 2024 |
pericles.pericles-prod.literatumonline.com | Zhiqiang Song |Yang Wang |Dongliang Zhang |TAO WANG
CONFLICT OF INTEREST STATEMENT The authors declare that they have no competing interests. Supporting Information Filename Description ijc35235-sup-0001-supinfo.pdfPDF document, 383.2 KB Data S1: Supporting Information REFERENCES 1, , , et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017; 376(9): 836-847. 2, , , et al.
-
Jun 21, 2024 |
mdpi.com | Yi Cheng |Jianping Xu |Zhiqiang Song |Jiayang Li
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Dec 2, 2023 |
mdpi.com | Zheng Ma |Zelin Zhang |Zhaohui Zhang |Zhiqiang Song
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →